BioCryst Pharmaceuticals (BCRX) CCO reports equity holdings details

Rhea-AI Filing Summary

BioCryst Pharmaceuticals' Chief Commercial Officer, Ronald Dullinger, has filed an initial Form 3 reporting his equity holdings in the company. As of 01/01/2026, he beneficially owns 258,372 shares of common stock, which include 206,813 restricted stock units that vest in four equal annual installments starting on each grant’s anniversary.

He also holds several employee stock options to purchase common stock, including grants for 100,000 shares at $2.85 per share expiring in 2029 and 100,000 shares at $8.31 per share expiring in 2030. Additional option awards cover smaller blocks of shares at exercise prices between $6.43 and $11.43, with expiration dates running through 2035. Each option grant vests 25% per year over four years from its grant date.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dullinger Ronald

(Last) (First) (Middle)

4505 EMPEROR BLVD

SUITE 200

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/01/2026

3. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	258,372(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Emp. Stock Option (Right to Buy)	11/29/2020(2)	11/29/2029	Common Stock	100,000	$2.85	D
Emp. Stock Option (Right to Buy)	12/15/2021(3)	12/15/2030	Common Stock	100,000	$8.31	D
Emp. Stock Option (Right to Buy)	12/14/2022(4)	12/14/2031	Common Stock	41,000	$11.43	D
Emp. Stock Option (Right to Buy)	12/19/2023(5)	12/19/2032	Common Stock	57,100	$10.63	D
Emp. Stock Option (Right to Buy)	12/14/2024(6)	12/14/2033	Common Stock	57,100	$6.43	D
Emp. Stock Option (Right to Buy)	12/19/2025(7)	12/19/2034	Common Stock	68,500	$7.39	D
Emp. Stock Option (Right to Buy)	12/17/2026(8)	12/17/2035	Common Stock	255,050	$7.13	D

Explanation of Responses:

1. Includes 206,813 restricted stock units which vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

2. Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on November 29, 2019.

3. Annual Employee Option Grant became exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 15, 2020.

4. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2021.

5. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2022.

6. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 14, 2023.

7. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 19, 2024.

8. Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. The option was granted on December 17, 2025.

Remarks:

Exhibit List: Exhibit 24 - Power of Attorney

	/s/ Alane P. Barnes, by power of attorney	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the BioCryst (BCRX) Form 3 filing report for Ronald Dullinger?

The Form 3 reports that Chief Commercial Officer Ronald Dullinger has disclosed his initial beneficial ownership in BioCryst Pharmaceuticals common stock and employee stock options as of 01/01/2026.

How many BioCryst (BCRX) common shares does Ronald Dullinger beneficially own?

Ronald Dullinger beneficially owns 258,372 shares of BioCryst common stock, including 206,813 restricted stock units that vest in four equal annual installments from their grant dates.

What stock options are reported for Ronald Dullinger in the BioCryst Form 3?

He holds multiple employee stock options (rights to buy) BioCryst common stock, including grants for 100,000 shares at $2.85 per share expiring in 2029 and 100,000 shares at $8.31 per share expiring in 2030, plus additional grants at higher prices with later expirations.

How do Ronald Dullinger’s BioCryst stock options vest?

Each annual employee option grant becomes exercisable at a rate of 25% on each of the first, second, third, and fourth anniversaries of its grant date, as described in the footnotes.

Are Ronald Dullinger’s BioCryst holdings direct or indirect?

The Form 3 indicates that both his common stock and his employee stock options are held with direct (D) ownership, with no separate entity listed for indirect ownership.

What is the purpose of this BioCryst (BCRX) Form 3 filing?

This Form 3 serves as an initial statement of beneficial ownership for officer Ronald Dullinger, disclosing his BioCryst common stock, restricted stock units, and stock option awards as required for company insiders.